Novo Nordisk's anti-TFPI antibody concizumab ... However, the two drugs are going after different indications. Alhemo is indicated for use in haemophilia A and B patients with inhibitors ...
Novo Nordisk got the go-ahead for its once-daily prophylactic haemophilia therapy Alhemo (concizumab ... It's the second drug in the TFPI class to be approved by the FDA after Pfizer's once ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback